Mustang Bio, INC. (MBIO) — SEC Filings

Overview

Mustang Bio, INC. (MBIO) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 23, 2025: Mustang Bio, Inc. filed an 8-K on December 23, 2025, reporting events that occurred on December 17, 2025. The filing indicates that the company is submitting matters to a vote of security holders and also includes other events and financial statements/exhibits. Specific details regarding the vote or

Sentiment Summary

Across 44 filings, the sentiment breakdown is: 7 bearish, 36 neutral, 1 mixed. The dominant filing sentiment for Mustang Bio, INC. is neutral.

Filing Type Overview

Mustang Bio, INC. (MBIO) has filed 26 8-K, 2 DEF 14A, 6 10-Q, 2 10-K, 3 S-1/A, 2 S-1, 1 SC 13G/A, 1 SC 13D/A, 1 SC 13G with the SEC between Jan 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (44)

• Mustang Bio Files 8-K for Shareholder Vote & Other Events — 8-K · Dec 23, 2025 Risk: medium
  Mustang Bio, Inc. filed an 8-K on December 23, 2025, reporting events that occurred on December 17, 2025. The filing indicates that the company is submitting ma
• Mustang Bio Seeks Shareholder Approval for Equity Plan Boosts, Director Slate — DEF 14A · Dec 3, 2025 Risk: high
  Mustang Bio, Inc. (MBIO) is holding its Annual Meeting on December 22, 2025, to address several critical proposals impacting its corporate governance and equity
• Mustang Bio Narrows Losses, Boosts Cash Amid Going Concern Doubts — 10-Q · Nov 7, 2025 Risk: high
  MUSTANG BIO, INC. (MBIO) reported a net loss of $468,000 for the three months ended September 30, 2025, a significant improvement from the $1.41 million net los
• Mustang Bio Navigates Cash Burn, Leans on Equity for Survival — 10-Q · Aug 8, 2025 Risk: high
  MUSTANG BIO, INC. reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-commercial stage. The company's net loss for the
• Mustang Bio Files 8-K: Corporate Updates — 8-K · Jul 9, 2025 Risk: low
  Mustang Bio, Inc. filed an 8-K on July 9, 2025, reporting other events and financial statements as of July 7, 2025. The filing details the company's principal e
• Mustang Bio Files Q1 2025 10-Q — 10-Q · May 14, 2025 Risk: medium
  Mustang Bio, Inc. filed its 10-Q for the period ending March 31, 2025. The company's financial statements show details regarding its common stock, additional pa
• Mustang Bio Files 2024 Annual Report — 10-K · Mar 28, 2025 Risk: medium
  Mustang Bio, Inc. filed its 10-K for the fiscal year ending December 31, 2024. The company, headquartered in Worcester, MA, operates in the pharmaceutical prepa
• Mustang Bio Files 8-K: Corporate Updates — 8-K · Mar 5, 2025 Risk: low
  Mustang Bio, Inc. filed an 8-K on March 5, 2025, reporting other events and financial statements. The filing details the company's principal executive offices l
• Mustang Bio Completes Asset Acquisition/Disposition — 8-K · Feb 27, 2025 Risk: medium
  Mustang Bio, Inc. reported on February 21, 2025, the completion of an acquisition or disposition of assets. The filing also includes other events and financial
• Mustang Bio Files 8-K on Security Holder Vote Matters — 8-K · Feb 21, 2025 Risk: medium
  Mustang Bio, Inc. filed an 8-K on February 21, 2025, reporting an event that occurred on February 19, 2025. The filing indicates a submission of matters to a vo
• Mustang Bio Terminates Material Definitive Agreement — 8-K · Feb 13, 2025 Risk: medium
  Mustang Bio, Inc. announced on February 7, 2025, the termination of a material definitive agreement. The company, incorporated in Delaware with its principal ex
• Mustang Bio Enters Material Definitive Agreement — 8-K · Feb 11, 2025 Risk: medium
  Mustang Bio, Inc. announced on February 5, 2025, that it has entered into a material definitive agreement. The company, incorporated in Delaware with its princi
• Mustang Bio Files S-1/A Amendment — S-1/A · Feb 5, 2025 Risk: medium
  Mustang Bio, Inc. filed an S-1/A on February 5, 2025, to amend its registration statement. The filing details various financial events and agreements, including
• Mustang Bio Sells Subsidiary, Focuses on Gene Therapy — 8-K · Jan 17, 2025 Risk: medium
  Mustang Bio, Inc. announced on January 14, 2025, that it has entered into a definitive agreement to sell its wholly-owned subsidiary, Mustang Bio Development, L
• Mustang Bio Files S-1 with SEC — S-1 · Jan 15, 2025 Risk: medium
  Mustang Bio, Inc. filed an S-1 form on January 15, 2025, detailing its financial status and offering information. The company, incorporated in Delaware with its
• Mustang Bio Files 8-K on Shareholder Vote Matters — 8-K · Jan 10, 2025 Risk: low
  Mustang Bio, Inc. filed an 8-K on January 10, 2025, to report on matters submitted to a vote of its security holders. The filing does not contain details about
• Mustang Bio Files 8-K on Shareholder Vote Matters — 8-K · Jan 2, 2025 Risk: low
  Mustang Bio, Inc. filed an 8-K on January 2, 2025, reporting on matters submitted to a vote of security holders as of December 26, 2024. The filing details the
• Mustang Bio Files Definitive Proxy Statement — DEF 14A · Dec 6, 2024 Risk: low
  Mustang Bio, Inc. filed its definitive proxy statement on December 6, 2024, for its annual meeting on December 26, 2024. The filing, under SEC Act of 1934, conc
• Mustang Bio Faces Nasdaq Delisting Warning — 8-K · Nov 15, 2024 Risk: high
  Mustang Bio, Inc. announced on November 12, 2024, that it received a notice from the Nasdaq Stock Market indicating non-compliance with listing rules. The compa
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• Mustang Bio Files Q3 2024 10-Q — 10-Q · Nov 8, 2024 Risk: medium
  Mustang Bio, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported its financial results and operational highlights. Key financial
• Mustang Bio Files 8-K on Shareholder Nominations — 8-K · Nov 6, 2024 Risk: medium
  Mustang Bio, Inc. filed an 8-K on November 6, 2024, to report on shareholder nominations pursuant to Exchange Act Rule 14a-11 and other events. The filing does
• Mustang Bio Announces CMO Departure, Equity Sales — 8-K · Oct 25, 2024 Risk: medium
  Mustang Bio, Inc. announced on October 23, 2024, the departure of its Chief Medical Officer, Dr. Manuel Litchman. The company also reported on unregistered sale
• Mustang Bio Faces Delisting Concerns — 8-K · Sep 13, 2024 Risk: high
  Mustang Bio, Inc. filed an 8-K on September 13, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The filing ind
• Mustang Bio Reports Q2 2024 Results, Equity Offerings — 10-Q · Aug 13, 2024 Risk: medium
  Mustang Bio, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported total assets of $34.1 million and total liabilities of $8.45 million.
• Mustang Bio Files S-1 for Undetermined Securities Offering — S-1 · Jul 19, 2024 Risk: medium
  Mustang Bio, Inc. filed an S-1 registration statement on July 19, 2024, to register an indeterminate number of securities to be offered from time to time. The c
• Mustang Bio Terminates Agreement, Completes Asset Deal — 8-K · Jul 3, 2024 Risk: medium
  Mustang Bio, Inc. announced on June 27, 2024, the termination of a material definitive agreement and the completion of an acquisition or disposition of assets.
• Fortress Biotech Amends Mustang Bio Stake Filing — SC 13D/A · Jun 28, 2024 Risk: medium
  Fortress Biotech, Inc. filed an amendment (No. 3) to its Schedule 13D on June 28, 2024, regarding its holdings in Mustang Bio, Inc. The filing indicates a chang
• Mustang Bio Enters Material Agreement, Reports Equity Sales — 8-K · Jun 24, 2024 Risk: medium
  Mustang Bio, Inc. announced on June 19, 2024, that it entered into a material definitive agreement. The company also reported on unregistered sales of equity se
• Mustang Bio Terminates Material Agreement — 8-K · Jun 6, 2024 Risk: medium
  Mustang Bio, Inc. announced on May 31, 2024, the termination of a material definitive agreement. The company also filed its financial statements and exhibits as
• Mustang Bio Faces Nasdaq Delisting Warning — 8-K · May 21, 2024 Risk: high
  Mustang Bio, Inc. announced on May 16, 2024, that it received a deficiency letter from the Nasdaq Stock Market indicating it is not in compliance with the minim
• Mustang Bio, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 15, 2024 Risk: medium
  MUSTANG BIO, INC. (MBIO) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. Mustang Bio reported total assets of $11,253,767 as of March 31, 2024. Th
• Mustang Bio Files 8-K for Material Agreement — 8-K · May 2, 2024 Risk: medium
  Mustang Bio, Inc. filed an 8-K on April 29, 2024, reporting the entry into a material definitive agreement and other events. The filing also includes financial
• Mustang Bio Files Amendment No. 3 to S-1 Registration Statement — S-1/A · Apr 29, 2024 Risk: low
  MUSTANG BIO, INC. (MBIO) filed a Amended IPO Registration (S-1/A) with the SEC on April 29, 2024. Mustang Bio, Inc. filed an S-1/A (Amendment No. 3) with the SE
• Mustang Bio Reports Exit/Disposal Costs — 8-K · Apr 12, 2024 Risk: medium
  Mustang Bio, Inc. filed an 8-K on April 12, 2024, reporting costs associated with exit or disposal activities as of April 10, 2024. The filing does not specify
• Mustang Bio Files Amendment No. 1 to S-1 Registration Statement — S-1/A · Apr 2, 2024 Risk: low
  MUSTANG BIO, INC. (MBIO) filed a Amended IPO Registration (S-1/A) with the SEC on April 2, 2024. Mustang Bio, Inc. filed an amendment (S-1/A) to its registratio
• Mustang Bio Sells Subsidiary, Exits Operations — 8-K · Mar 29, 2024 Risk: high
  Mustang Bio, Inc. announced on March 28, 2024, that it has entered into a definitive agreement to sell its wholly-owned subsidiary, Mustang Bio Holdings, Inc.,
• Mustang Bio Faces Nasdaq Delisting Warning — 8-K · Mar 15, 2024 Risk: high
  Mustang Bio, Inc. announced on March 13, 2024, that it received a notification from The Nasdaq Stock Market indicating a failure to meet the minimum bid price r
• Mustang Bio Files 8-K for Operations and Financials — 8-K · Mar 11, 2024 Risk: low
  Mustang Bio, Inc. filed an 8-K on March 11, 2024, to report on its results of operations and financial condition, as well as to file financial statements and ex
• Mustang Bio, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 11, 2024 Risk: medium
  MUSTANG BIO, INC. (MBIO) filed a Annual Report (10-K) with the SEC on March 11, 2024. Mustang Bio, Inc. filed its annual report for the fiscal year ended Decemb
• SC 13G Filing — SC 13G · Feb 14, 2024
• Mustang Bio Files 8-K for Undisclosed 'Other Event' — 8-K · Feb 14, 2024 Risk: medium
  Mustang Bio, Inc. filed an 8-K Current Report with the SEC on February 14, 2024, reporting an "Other Event" that occurred on February 12, 2024. The filing indic
• Mustang Bio Reports Officer/Director Changes, Comp Arrangements — 8-K · Jan 25, 2024
  Mustang Bio, Inc. filed an 8-K on January 25, 2024, reporting an event that occurred on January 19, 2024. The filing indicates changes related to the departure
• Mustang Bio Files Routine 8-K, No New Material Info — 8-K · Jan 4, 2024
  Mustang Bio, Inc. filed an 8-K on January 4, 2024, reporting an "Other Event" that occurred on December 28, 2023. This filing simply confirms the company's basi

Risk Profile

Risk Assessment: Of MBIO's 40 recent filings, 8 were flagged as high-risk, 24 as medium-risk, and 8 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Mustang Bio, INC.'s most recent 10-Q filing (Nov 7, 2025):

• Net Income: $(1,383,000)
• Cash Position: $18,984,000
• Total Assets: $19,361,000

Key Executives

• Manuel Litchman, M.D.
• Peter Carney
• Dr. Manuel Litchman
• Rakesh Gopalan
• Joseph Walsh
• Lindsay A. Rosenwald, M.D.

Industry Context

Mustang Bio operates in the biotechnology sector, focusing on developing cell therapies for cancer and other serious diseases. This industry is characterized by high research and development costs, long development timelines, and significant regulatory hurdles. Companies in this space often rely on equity financing and strategic partnerships to fund their operations and advance their pipelines.

Top Tags

corporate-governance (6) · Biotechnology (5) · 10-Q (5) · financials (5) · shareholder-vote (4) · SEC Filing (4) · material-agreement (4) · agreement-termination (3) · biotech (3) · compliance (3)

Key Numbers

• Annual Meeting Date: 2025-12-22 — Date stockholders will vote on proposals
• Increase in 2019 Employee Stock Purchase Plan: 250,000 shares — Proposed increase in shares available for employee purchases
• Maximum Purchase Right per Employee: 10,000 shares — Proposed increase in shares an employee can purchase under ESPP
• Increase in 2016 Incentive Plan: 2,500,000 shares — Proposed increase in shares available for equity compensation
• Reverse Stock Split Ratio: 1-for-50 — Effective January 15, 2025, consolidating shares
• Common Stock Outstanding: 6,453,701 shares — As of November 18, 2025, Record Date
• Class A Common Stock Outstanding: 845,385 shares — As of November 18, 2025, Record Date
• Class A Preferred Stock Outstanding: 250,000 shares — As of November 18, 2025, Record Date
• Record Date: 2025-11-18 — Date for determining stockholders entitled to vote
• Cash and Cash Equivalents: $18.984M — Increased from $6.839M at Dec 31, 2024, providing short-term liquidity.
• Net Loss (Q3 2025): $(468K) — Significantly improved from $(1.41M) in Q3 2024, indicating reduced burn.
• Net Loss (9M 2025): $(1.383M) — Substantially lower than $(14.8M) in 9M 2024, showing a positive trend in loss reduction.
• Research and Development Expenses (9M 2025): $(1.199M) — Dramatic decrease from $8.221M in 9M 2024, suggesting a significant shift in R&D strategy or activity.
• Net Cash from Financing Activities (9M 2025): $14.526M — Primary driver of increased cash, including $7.145M from warrant exercises.
• Common Shares Outstanding: 6,453,701 — As of September 30, 2025, reflecting dilution from equity offerings and warrant exercises.

Related Companies

FBIO · FBRX · NASDAQ:MBIO

Frequently Asked Questions